CD4+Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease

Persistent hepatotropic viral infections are a common etiologic agent of chronic liver disease. Unresolved infection can be attributed to non-functional intrahepatic CD8+ T cell responses. In light of dampened CD8+ T cell responses, liver disease often manifests systemically as Ig-related syndromes due to aberrant B cell functions. These two opposing yet co-existing phenomena implicate the potential of altered CD4+ T cell help. Elevated CD4+ Foxp3+ T cells were evident in both human liver disease and a mouse model of chemically induced liver injury despite marked activation and spontaneous IgG production by intrahepatic B cells. While this population suppressed CD8+ T cell responses, aberrant B cell activities were maintained due to expression of CD40L on a subset of CD4+ Foxp3+ T cells. In vivo blockade of CD40L attenuated B cell abnormalities in a mouse model of liver injury. A phenotypically similar population of CD4+ Foxp3+ CD40L+ T cells was found in diseased livers explanted from patients with chronic hepatitis C infection. This population was absent in non-diseased liver tissues and peripheral blood. Conclusion—Our data indicate that liver disease elicits alterations in the intrahepatic CD4+ T cell compartment that suppress T cell immunity while concomitantly promoting aberrant IgGmediated manifestations.

[1]  A. Lawson,et al.  CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study , 2015, Arthritis Research & Therapy.

[2]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[3]  B. Pulendran,et al.  Liver fibrosis occurs through dysregulation of MyD88‐dependent innate B‐cell activity , 2015, Hepatology.

[4]  Xuyu Zhou,et al.  Regulatory T cells turn pathogenic , 2015, Cellular and Molecular Immunology.

[5]  A. Kirk,et al.  Systems biological analyses reveal the hepatitis C virus (HCV)‐specific regulation of hematopoietic development , 2015, Hepatology.

[6]  S. Crotty A brief history of T cell help to B cells , 2015, Nature Reviews Immunology.

[7]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[8]  Yuanqing Liu,et al.  A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species , 2014, Front. Immunol..

[9]  Simon A. Jones,et al.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity , 2014, Nature Reviews Immunology.

[10]  J. Fallowfield,et al.  Liver fibrosis and repair: immune regulation of wound healing in a solid organ , 2014, Nature Reviews Immunology.

[11]  R. Schwabe,et al.  Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.

[12]  Y. Oo,et al.  Regulatory T-cell directed therapies in liver diseases. , 2013, Journal of hepatology.

[13]  D. Stainier,et al.  Hepatic stellate cells in liver development, regeneration, and cancer. , 2013, The Journal of clinical investigation.

[14]  B. Pulendran,et al.  Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid , 2013, The Journal of Immunology.

[15]  D. Busch,et al.  Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice , 2012, Hepatology.

[16]  Carola G. Vinuesa,et al.  Foxp3(+) follicular regulatory T cells control the germinal centre response , 2012 .

[17]  Herman Waldmann,et al.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.

[18]  S. Ichikawa,et al.  Hepatic Stellate Cells Function as Regulatory Bystanders , 2011, The Journal of Immunology.

[19]  B. Baban,et al.  Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. , 2010, Immunity.

[20]  Y. Hsu,et al.  Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice , 2010, The Journal of Immunology.

[21]  Lieping Chen,et al.  PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells , 2010, Nature Immunology.

[22]  R. D. de Knegt,et al.  Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. , 2010, Journal of hepatology.

[23]  J. Atkinson,et al.  CD46‐induced human Treg enhance B‐cell responses , 2009, European journal of immunology.

[24]  G. Labbadia,et al.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. , 2009, The Journal of clinical investigation.

[25]  D. Adams,et al.  Immune-mediated liver injury. , 2007, Seminars in liver disease.

[26]  A. Rudensky,et al.  Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.

[27]  A. Rudensky,et al.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3 , 2007, Nature Immunology.

[28]  K. Tsuneyama,et al.  Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis , 2006, Hepatology.

[29]  P. Lipsky,et al.  The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[30]  J. Cobb,et al.  Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. , 2006, Blood.

[31]  M. Shlomchik,et al.  Attenuated liver fibrosis in the absence of B cells. , 2005, The Journal of clinical investigation.

[32]  Jörg Köhl,et al.  Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans , 2005, Nature Genetics.

[33]  H. Blum,et al.  T Cells with a CD4+CD25+ Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8+ T Cells during Chronic Hepatitis C Virus Infection , 2005, Journal of Virology.

[34]  B. Rehermann,et al.  The liver as an immunological organ , 2004 .

[35]  C. Walker,et al.  Cell-mediated immunity and the outcome of hepatitis C virus infection. , 2004, Annual review of microbiology.

[36]  Zhao-chun Chi,et al.  Rheumatologic manifestations of hepatic diseases. , 2003, Hepatobiliary & pancreatic diseases international : HBPD INT.

[37]  Felicia A Tucci,et al.  Molecular Characterization of B Cell Clonal Expansions in the Liver of Chronically Hepatitis C Virus-Infected Patients1 , 2001, The Journal of Immunology.

[38]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand , 2000, Nature Medicine.

[39]  S. Kalled,et al.  Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. , 1998, Journal of immunology.

[40]  R. Ahmed,et al.  CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection , 1996, Journal of virology.

[41]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[42]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[43]  R. Willson Extrahepatic manifestations of chronic viral hepatitis. , 1997, The American journal of gastroenterology.